XGN
Exagen Inc. NASDAQ Listed Sep 19, 2019$2.94
Mkt Cap $70.7M
52w Low $2.59
3.6% of range
52w High $12.23
50d MA $3.06
200d MA $6.81
P/E (TTM)
-3.3x
EV/EBITDA
-8.7x
P/B
3.8x
Debt/Equity
0.3x
ROE
-114.3%
P/FCF
-9.2x
RSI (14)
—
ATR (14)
—
Beta
1.94
50d MA
$3.06
200d MA
$6.81
Avg Volume
319.0K
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
1261 Liberty Way · Vista, CA 92081 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | -0.20 | -0.20 | +0.0% | 3.25 | -2.5% | -4.3% | +1.6% | -2.8% | +2.9% | +0.3% | — |
| Nov 4, 2025 | AMC | -0.13 | -0.19 | -46.2% | 10.77 | +0.7% | -4.1% | +0.5% | -7.9% | -1.0% | -2.5% | — |
| Jul 29, 2025 | AMC | -0.18 | -0.18 | +0.0% | 8.45 | +4.4% | +2.1% | -2.7% | +2.7% | +2.5% | +0.2% | — |
| May 5, 2025 | AMC | -0.20 | -0.20 | +0.0% | 6.25 | -1.1% | +2.7% | +6.4% | -9.8% | -7.3% | +1.1% | — |
| Mar 11, 2025 | AMC | -0.27 | -0.20 | +25.9% | 3.37 | +1.5% | -1.2% | +0.6% | +6.3% | +1.7% | +0.0% | — |
| Nov 12, 2024 | AMC | -0.30 | -0.28 | +6.7% | 2.79 | +4.7% | -1.4% | +5.5% | +2.8% | +0.7% | +17.7% | — |
| Aug 5, 2024 | AMC | -0.36 | -0.16 | +55.6% | 2.40 | +0.0% | +0.0% | +2.1% | +12.7% | +22.5% | -0.6% | — |
| May 13, 2024 | AMC | -0.40 | -0.19 | +52.5% | 1.64 | -0.6% | +7.3% | +8.5% | -1.0% | -0.5% | -0.5% | — |
| Mar 18, 2024 | AMC | -0.41 | -0.31 | +24.4% | 1.77 | -4.0% | -13.0% | +4.5% | +3.7% | -3.6% | -11.8% | — |
| Nov 13, 2023 | AMC | -0.50 | -0.31 | +38.0% | 1.46 | +6.8% | +16.4% | -9.1% | +3.6% | -1.8% | -0.8% | — |
| Aug 7, 2023 | AMC | -0.48 | -0.28 | +41.7% | 2.73 | +1.5% | +1.5% | -7.2% | +2.3% | -2.7% | -1.9% | — |
| May 15, 2023 | AMC | -0.52 | -0.44 | +15.4% | 2.91 | -0.1% | +19.5% | -6.9% | -2.8% | -1.0% | +1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.08 | $3.08 | +0.0% | -2.9% | -2.7% | -1.4% | -6.6% | +0.7% |
| Mar 11 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $3.25 | $3.17 | -2.5% | -4.3% | +1.6% | -2.8% | +2.9% | +0.3% |
| Mar 11 | Craig-Hallum | Maintains | Buy → Buy | — | $3.25 | $3.17 | -2.5% | -4.3% | +1.6% | -2.8% | +2.9% | +0.3% |
| Mar 11 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.25 | $3.17 | -2.5% | -4.3% | +1.6% | -2.8% | +2.9% | +0.3% |
| Mar 10 | BTIG | Maintains | Buy → Buy | — | $3.38 | $3.40 | +0.6% | -3.8% | -4.3% | +1.6% | -2.8% | +2.9% |
| Feb 24 | TD Cowen | Maintains | Buy → Buy | — | $3.70 | $3.70 | +0.0% | -0.3% | +3.0% | +0.0% | -4.7% | -1.9% |
| Feb 17 | BTIG | Maintains | Buy → Buy | — | $3.28 | $3.22 | -1.8% | +0.9% | -0.9% | -0.3% | +4.3% | +8.5% |
| Jan 30 | B. Riley Securities | Maintains | Buy → Buy | — | $3.95 | $3.95 | +0.0% | -6.8% | +4.1% | -3.1% | -5.4% | -4.3% |
| Nov 10 | BTIG | Maintains | Buy → Buy | — | $9.56 | $9.82 | +2.7% | -1.0% | -2.5% | +4.0% | -2.5% | -3.6% |
| Nov 5 | B. Riley Securities | Maintains | Buy → Buy | — | $10.77 | $10.84 | +0.7% | -4.1% | +0.5% | -7.9% | -1.0% | -2.5% |
| Oct 27 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.96 | $12.11 | +1.3% | -0.4% | -0.2% | -0.3% | -0.8% | -0.8% |
| Oct 22 | BTIG | Maintains | Buy → Buy | — | $11.69 | $11.72 | +0.3% | +0.5% | +1.4% | +0.3% | -0.4% | -0.2% |
| Oct 14 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $11.04 | $11.25 | +1.9% | +4.5% | +3.3% | -1.3% | -2.0% | +1.6% |
| Jul 30 | KeyBanc Capital Markets | Upgrade | Sector Weight → Overweight | — | $8.45 | $8.82 | +4.4% | +2.1% | -2.7% | +2.7% | +2.5% | +0.2% |
| Jul 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.45 | $8.82 | +4.4% | +2.1% | -2.7% | +2.7% | +2.5% | +0.2% |
| May 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.82 | $5.74 | -1.4% | -1.4% | +4.7% | +5.3% | -5.8% | -3.2% |
| May 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.77 | $5.77 | +0.0% | -2.4% | +3.4% | -1.4% | +4.7% | +5.3% |
| Jan 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.17 | $3.17 | +0.0% | -1.6% | -3.8% | +4.0% | -1.9% | +30.4% |
| Jan 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.09 | $3.05 | -1.3% | +15.9% | -5.3% | -3.5% | +0.6% | -3.6% |
| May 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.64 | $1.63 | -0.6% | +7.3% | +8.5% | -1.0% | -0.5% | -0.5% |
| Sep 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.24 | $2.29 | +2.2% | +6.2% | +6.3% | -3.2% | -1.2% | -1.2% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.56 | $2.58 | +1.0% | -0.4% | +1.3% | -1.6% | +1.4% | -3.0% |
| May 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.91 | $2.91 | -0.1% | +19.5% | -6.9% | -2.8% | -1.0% | +1.9% |
| Mar 22 | BTIG | Maintains | Buy → Buy | — | $2.30 | $2.30 | +0.0% | -2.8% | +0.7% | -0.9% | +3.3% | -2.4% |
| Nov 17 | BTIG | Maintains | Buy → Buy | — | $3.40 | $3.23 | -5.0% | -9.7% | -4.2% | -7.1% | -6.6% | +33.3% |
| Nov 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.10 | $2.25 | +7.1% | +42.4% | +13.7% | -9.7% | -4.2% | -7.1% |
| May 13 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $5.28 | $5.35 | +1.3% | -8.5% | -5.0% | +3.5% | -8.6% | -3.7% |
| Mar 25 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $8.59 | $8.52 | -0.8% | -2.2% | +0.0% | -4.4% | -0.4% | +0.4% |
| Nov 11 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $13.20 | $13.79 | +4.5% | +6.2% | -8.2% | -1.5% | -1.3% | -1.5% |
| Apr 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $16.69 | $17.59 | +5.4% | +4.4% | -4.6% | -1.3% | -3.5% | -3.4% |
| Mar 2 | KeyBanc | Maintains | Overweight → Overweight | — | $19.56 | $19.71 | +0.8% | +6.7% | -2.1% | -4.6% | -2.4% | +7.5% |
| Mar 2 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $19.56 | $19.71 | +0.8% | +6.7% | -2.1% | -4.6% | -2.4% | +7.5% |
| Mar 1 | KeyBanc | Maintains | Overweight → Overweight | — | $18.29 | $18.89 | +3.3% | +6.9% | +6.7% | -2.1% | -4.6% | -2.4% |
| Nov 10 | KeyBanc | Maintains | Overweight → Overweight | — | $15.55 | $16.35 | +5.1% | +3.2% | -2.2% | -2.9% | -3.0% | +3.9% |
| Oct 8 | BTIG | Maintains | Buy → Buy | — | $13.38 | $13.85 | +3.5% | +5.9% | +1.3% | +3.5% | -0.9% | +1.2% |
| Nov 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $19.49 | $19.99 | +2.6% | -1.3% | -2.8% | +5.3% | -1.9% | -1.1% |
| Oct 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $12.61 | $13.05 | +3.5% | +3.1% | +0.0% | -0.4% | +4.3% | +3.6% |
| Oct 14 | Cowen & Co. | Maintains | Outperform → Outperform | — | $12.61 | $13.05 | +3.5% | +3.1% | +0.0% | -0.4% | +4.3% | +3.6% |
| Oct 14 | William Blair | Maintains | Outperform → Outperform | — | $12.61 | $13.05 | +3.5% | +3.1% | +0.0% | -0.4% | +4.3% | +3.6% |
No insider trades available.
8-K · 5.02
!!! Very High
Exagen Inc. -- 8-K 5.02: Executive Change
Exagen Inc. lost director Ana Hooker, who resigned effective April 17, 2026, potentially reducing board expertise and oversight capacity.
Apr 23
8-K
Unknown — 8-K Filing
Exagen's record revenue and 11% test volume growth demonstrate strong market traction, but investors should monitor whether the biomarker expansion and sales force investments can sustain this momentum and improve profitability.
Mar 10
Data updated apr 27, 2026 10:31am
· Source: massive.com